title: Cefaclor AF vs Clarithromycin in acute exacerbation of chronic bronchitis (B3M-PK-AJBG).
abstract: OBJECTIVE
  To compare the efficacy and safety of Cefaclor AF vs Clarithromycin in the treatment of acute exacerbation of chronic bronchitis in adult subjects.
  
  
  METHODS
  This study was conducted on 300 patients suffering from acute exacerbation of chronic bronchitis, who attended the out patient clinics of ten different hospitals throughout Pakistan. Pneumonia, bronchiectasis and tuberculosis were excluded with the help of chest radiography and sputum smear examination. Pretherapy sputum culture and sensitivity (c/s) were tested and patients were randomized and supplied with either tablet Cefaclor 375 mg or tablet Clarithromycin 250 mg to be taken twice daily. Patients were evaluated at day 0 and then at day 3-5 and day 10-11. Post therapy sputum c/s was done on day 10-11. A fourth and final visit was planned on day 20-24 which was optional. At each visit, the severity of disease and the signs and symptoms were recorded on the clinical report forms according to the preset standards.
  
  
  RESULTS
  Of 136 patients in the Cefaclor group and 142 patients in the Clarithromycin group, cure was achieved in 44 vs 35 subjects, improvement in 78 vs 91 subjects and failure in 16 vs 18 subjects among Cefaclor vs Clarithromycin groups respectively. The overall clinical efficacy (cure and improvement combined ) was 88.4% in the Cefaclor group and 87.5% in the Clarithromycin group. Nine patients in the Cefaclor group and patients in the Clarithromycin group had one adverse event whereas twelve patients in each group had two or more adverse events.
  
  
  CONCLUSIONS
  The above results show that both Cefaclor AF and Clarithromycin are equally effective and safe in the treatment of acute exacerbation of chronic bronchitis in adult patients.
authors.affiliation: Fauji Foundation, Rawalpindi.
authors.forename: S
authors.initials: S
authors.lastname: Khan
authors.forename: A
authors.initials: A
authors.lastname: Javaid
authors.forename: R A
authors.initials: RA
authors.lastname: Ghori
authors.forename: K
authors.initials: K
authors.lastname: Mahmood
authors.forename: N
authors.initials: N
authors.lastname: Anwer
authors.forename: S U
authors.initials: SU
authors.lastname: Khan
authors.forename: Z H
authors.initials: ZH
authors.lastname: Iqbal
authors.forename: F
authors.initials: F
authors.lastname: Rahman
authors.forename: S
authors.initials: S
authors.lastname: Ullah
authors.forename: K
authors.initials: K
authors.lastname: Imran
authors.forename: N
authors.initials: N
authors.lastname: Akhter
authors.forename: M K Z
authors.initials: MK
authors.lastname: Khan
authors.forename: S J
authors.initials: SJ
authors.lastname: Siddqui
authors.forename: A
authors.initials: A
authors.lastname: Fareed
authors.forename: M H
authors.initials: MH
authors.lastname: Khan
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D029481:Bronchitis, Chronic / Q000188:drug therapy* / Q000382:microbiology; D002433:Cefaclor / Q000009:adverse effects / Q000627:therapeutic use*; D017291:Clarithromycin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016037:Single-Blind Method; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D002433:Cefaclor; D017291:Clarithromycin